Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Forecasted Market Size Estimates For The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Between 2025 And 2029?
The nucleic acid and gene therapies in neuromuscular disorders market has seen robust expansion in recent years. Its valuation is set to increase from $6.84 billion in 2024 to $7.5 billion in 2025, showing a compound annual growth rate (CAGR) of 9.6%. This historical growth can be attributed to several factors, including an increase in regulatory approvals, the escalating demand for nucleic acid therapeutics, the need for more precise and effective treatments, the pursuit of effective gene therapies, and a rise in gene therapy-based discoveries.
The nucleic acid and gene therapies in neuromuscular disorders market size is projected to experience substantial expansion over the coming years. This market is set to reach $10.78 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.5%. This anticipated growth during the forecast period stems from factors such as the rising incidence of genetic disorders, increased funding in research and development, an expanding need for precision medicine, the growing approval of gene therapy products, and the heightened occurrence of chronic disorders. Key developments expected within this period encompass improvements in patient care, advancements in high-performance chromatography, the introduction of novel solutions for various conditions, progress in gene editing technologies, and the accessibility of nucleic acid extraction technology.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp
Which Drivers Are Shaping The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Industry’s Market Share?
The expanding occurrence of genetic disorders is projected to boost the expansion of the nucleic acid and gene therapies in neuromuscular disorders market in the future. These are conditions stemming from irregularities in a person’s DNA, which can be either inherited or develop from mutations. The rise in genetic disorders can be attributed to elements like genetic mutations, environmental factors, changes in lifestyle, and enhanced diagnostic capabilities. Nucleic acid and gene therapies offer a solution to genetic disorders by mending or substituting faulty genes in neuromuscular conditions, thereby working to restore normal physiological function. For example, data from May 2024, provided by Cure SMA, a US-based non-profit organization, indicates that in the United States, approximately 9,000 to 9,500 individuals are currently living with Spinal Muscular Atrophy (SMA). Among this total, 37% have Type 2 SMA, and the condition’s estimated incidence rate is 1 in 15,000 births. Consequently, the growing incidence of genetic disorders is fueling the expansion of the nucleic acid and gene therapies in neuromuscular disorders market.
What Are The Different Segment Classifications Within The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
The nucleic acid and gene therapies in neuromuscular disordersmarket covered in this report is segmented –
1) By Disorder: Motor Neuron Diseases; Neuropathies; Neuromuscular Junction Disorders; Myopathies Including Muscular Dystrophies
2) By Therapy: Adeno-Associated Viruses Gene Therapy; Postnatal Gene Therapy; Spinal Muscular Atrophy
3) By Application: Hospitals; Specialty Clinics; Ambulatory Surgery Centers
Subsegments:
1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS); Spinal Muscular Atrophy (SMA); Primary Lateral Sclerosis (PLS)
2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT); Hereditary Sensory and Autonomic Neuropathy (HSAN); Peripheral Neuropathies
3) By Neuromuscular Junction Disorders: Myasthenia Gravis; Lambert-Eaton Myasthenic Syndrome (LEMS)
4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD); Becker Muscular Dystrophy (BMD); Limb-Girdle Muscular Dystrophy (LGMD); Facioscapulohumeral Muscular Dystrophy (FSHD)
Which Competitive Trends Are Defining The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Structure?
Major companies are actively involved in the nucleic acid and gene therapies in neuromuscular disorders market, concentrating on developing pioneering treatments, such as gene therapy, to address the core causes of genetic neuromuscular conditions through precise gene correction or replacement. Gene therapy itself describes the method of treating illnesses by introducing, modifying, or repairing genetic material within a patient’s cells to either correct or substitute faulty genes. For instance, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, secured approval from the U.S. Food and Drug Administration for Elevidys, representing the first gene therapy for Duchenne Muscular Dystrophy, specifically intended for ambulatory pediatric patients aged 4 to 5 years. This therapy is given as a single intravenous infusion, simplifying the treatment process when compared to other therapies that might demand continuous infusions. ELEVIDYS delivers a gene that codes for a shortened form of dystrophin known as micro-dystrophin, which is vital for muscle function. This novel approach targets the underlying genetic defect by enabling muscle cells to produce a functional version of the dystrophin protein, thus potentially halting or even reversing the progression of the disease.
Which Major Industry Participants Are Leading The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Growth?
Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A, Novartis AG, Eli Lilly and Company, Astellas Pharma Inc, Biogen Inc, Vertex Pharmaceuticals Inc, BioMarin Pharmaceuticals Inc, Nippon Shinyaku Co Ltd, Sarepta Therapeutics Inc, Ionis Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc, Amicus Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Regenxbio Inc, UniQure N.V., Généthon S.A, Axovant Gene Therapies Inc.
Download The Full Report For Exclusive Market Findings:
How Do Regional Market Performances Compare Within The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Industry?
North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2024. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21233&type=smp
Browse Through More Reports Similar to the Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market 2025, By The Business Research Company
Isothermal Nucleic Acid Amplification Technology Global Market Report 2025
Nucleic Acid Based Gene Therapy Global Market Report 2025
Nucleic Acid Isolation And Purification Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model